Skopos Labs, Inc. Savara Inc Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Savara Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 23,611 shares of SVRA stock, worth $99,166. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,611
Previous 23,611
-0.0%
Holding current value
$99,166
Previous $65,000
18.46%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SVRA
# of Institutions
125Shares Held
167MCall Options Held
38.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD24.5MShares$103 Million4.63% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$73.9 Million12.04% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$51.9 Million5.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$48.1 Million1.38% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$46.3 Million1.32% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $479M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.